One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Tarsus Pharmaceuticals cleared that benchmark Monday, with a jump from 79 to 84 Monday.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 in the early stages of their moves.
Tarsus Pharmaceuticals has moved more than 5% past a 40.40 entry in a second-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Tarsus Pharmaceuticals reported 0% earnings growth in the latest quarterly report. Sales gains came in at 184%.
The company earns the No. 65 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
